+30.7%
GLW vs MRNA
+698.9%
-668.2%
-59.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.0% | +1.3% | -3.3% | -2.0% |
| 7D | -11.1% | -13.8% | +2.7% | -11.1% |
| 30D | -19.7% | -17.7% | -2.0% | -19.6% |
| 3M | -30.2% | +14.3% | -44.5% | -29.9% |
| 6M | -39.4% | +336.0% | -375.4% | -41.1% |
| YTD | +22.0% | +575.9% | -554.0% | +10.2% |
| 1Y | +30.7% | +724.4% | -693.6% | +7.8% |
| All | +30.7% | +698.9% | -668.2% | +7.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling